资金流向方面，主力资金净流入172.61万元，大单买入839.41万元，占比26.94%，卖出666.80万元，占 比21.40%。 昊海生科今年以来股价跌15.47%，近5个交易日跌0.59%，近20日跌0.53%，近60日跌11.97%。 资料显示，上海昊海生物科技股份有限公司位于上海市长宁区虹桥路1386号文广大厦23楼，成立日期 2007年1月24日，上市日期2019年10月30日，公司主营业务涉及医疗器械和药品研发、生产和销售。主 营业务收入构成为：医疗美容与创面护理产品44.12%，眼科产品28.18%，骨科产品17.39%，防粘连及 止血产品8.46%，其他产品1.86%。 昊海生科所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、医疗美容、 中盘、融资融券、H股等。 截至9月30日，昊海生科股东户数8388.00，较上期增加7.44%；人均流通股0股，较上期增加0.00%。 2025年1月-9月，昊海生科实现营业收入18.99亿元，同比减少8.47%；归母净利润3.05亿元，同比减少 10.63%。 11月25日，昊海生科盘中上涨2.13%，截至13:48，报50.38 ...

Core Viewpoint - The stock price of Haohai Biological Technology Co., Ltd. has shown fluctuations, with a recent increase of 2.01% on November 10, 2023, despite a year-to-date decline of 13.94% [1][2]. Company Overview - Haohai Biological Technology, established on January 24, 2007, and listed on October 30, 2019, is located in Shanghai and specializes in the research, production, and sales of medical devices and pharmaceuticals [2]. - The company's main revenue sources are: medical beauty and wound care products (44.12%), ophthalmic products (28.18%), orthopedic products (17.39%), anti-adhesion and hemostatic products (8.46%), and other products (1.86%) [2]. Financial Performance - For the period from January to September 2025, Haohai Biological reported a revenue of 1.899 billion yuan, a year-on-year decrease of 8.47%, and a net profit attributable to shareholders of 305 million yuan, down 10.63% year-on-year [2]. - The company has distributed a total of 891 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 7.44% to 8,388, with an average of 0 shares per shareholder [2]. - Hong Kong Central Clearing Limited is the seventh largest circulating shareholder, holding 5.6048 million shares, an increase of 2.617 million shares from the previous period [3]. Market Activity - On November 10, 2023, the stock traded at 51.29 yuan per share, with a total market capitalization of 11.929 billion yuan and a trading volume of 28.2676 million yuan [1]. - The net inflow of main funds was 2.4664 million yuan, with large orders accounting for 20.66% of purchases and 11.93% of sales [1].